Adjuvant denosumab for early breast cancer-Evidence and controversy.

Abstract

The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival.

However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.

References:

Loibl S., André F., Bachelot T., Barrios C.H., Bergh J., Burstein H.J., et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159–182. doi: 10.1016/j.annonc.2023.11.016.
Gradishar W.J., Moran M.S., Abraham J., Abramson V., Aft R., Agnese D., et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2024;22:331–357. doi: 10.6004/jnccn.2024.0035.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–1361. doi: 10.1016/S0140-6736(15)60908-4.
Gnant M., Pfeiler G., Dubsky P.C., Hubalek M., Greil R., Jakesz R., et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2015;386:433–443. doi: 10.1016/S0140-6736(15)60995-3.
Gnant M., Frantal S., Pfeiler G., Steger G.G., Egle D., Greil R., et al. Long-term outcomes of adjuvant denosumab in breast cancer. NEJM Evid. 2022;1 doi: 10.1056/EVIDoa2200162.

Article info

Journal issue:

Volume: 78
Issue: not provided

Doi:

10.1016/j.breast.2024.103826

More resources:

Elsevier Science

Full Text Sources

Free resource

MedlinePlus Health Information

Medical

Free resource

PubMed Central

Full Text Sources

Free resource

ClinicalKey

Full Text Sources

Paid

Adjuvant denosumab for early breast cancer-Evidence and controversy.

Abstract

References:

Loibl S., André F., Bachelot T., Barrios C.H., Bergh J., Burstein H.J., et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159–182. doi: 10.1016/j.annonc.2023.11.016.
Gradishar W.J., Moran M.S., Abraham J., Abramson V., Aft R., Agnese D., et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2024;22:331–357. doi: 10.6004/jnccn.2024.0035.
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–1361. doi: 10.1016/S0140-6736(15)60908-4.
Gnant M., Pfeiler G., Dubsky P.C., Hubalek M., Greil R., Jakesz R., et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2015;386:433–443. doi: 10.1016/S0140-6736(15)60995-3.
Gnant M., Frantal S., Pfeiler G., Steger G.G., Egle D., Greil R., et al. Long-term outcomes of adjuvant denosumab in breast cancer. NEJM Evid. 2022;1 doi: 10.1056/EVIDoa2200162.